• Insulin and Oral Antidiabetic, Insulin, Human Detemir
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with type 1 or type 2 diabetes mellitus.
    Dosage Administration: Dose depends on blood glucose, response, and many other factors. SC: Adults and Children > 2 yr: Type 2 diabetes patients who are insulin-naïve: 0.1 – 0.2 units/kg once daily in the evening (or divided into a twice daily regimen) or 10 units once daily in the evening (or divided into a twice daily regimen). Patients with type 1 or 2 diabetes receiving basal insulin or basal bolus therapy: may substitute on an equivalent unit-per-unit basis.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin, Human Aspart
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with type 1 or type 2 diabetes mellitus.
    Dosage Administration: SC: Adults and Children: Determined by needs of the patients; generally 0.5 – 1 units/kg/day total. 50 – 70% may be given as insulin aspart, and the remainder as intermediate- or long-acting insulin. May also be given via subcutaneous infusion pump; initial programming based on total daily dose of insulin given in previous regimen with 50% of total daily dose given as premeal boluses and 50% of total daily dose given as basal infusion; dose can then be adjusted based on response.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin Zinc Suspension (Insulin Lente)
    Dosage form: Injection
    Strength: 100U/ml in 10ml vial
    Indications/Special comments: Diabetes mellitus (long acting)
    Dosage Administration: By subcutaneous injection, according to requirements.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin Human NPH/Regular 70/30 Mix
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with type 1 or type 2 diabetes mellitus
    Dosage Administration: SC: Adults and Children: Determined by needs of the patients; generally 0.5 – 1 units/kg/day total. 50 – 70% may be given as insulin aspart, and the remainder as intermediate- or long-acting insulin. May also be given via subcutaneous infusion pump; initial programming based on total daily dose of insulin given in previous regimen with 50% of total daily dose given as premeal boluses and 50% of total daily dose given as basal infusion; dose can then be adjusted based on response.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin Human Lispro 75/25 (insulin lispro + protamine)
    Dosage form: Injection
    Strength: n/a
    Indications/Special comments: Humalog Mix 75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro, is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycaemia. Humalog Mix 75/25 has a more rapid onset of glucose-lowering activity compared to Humulin 70/30 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.
    Dosage Administration: Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of activity. Therefore, the dose of Humalog Mix75/25 should be given within 15 minutes before a meal. See product insert for further information
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin Human Lispro
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: A fast-acting form of insulin that works by lowering levels of glucose (sugar) in the blood. Insulin lispro is used to treat type 1 (insulin-dependent) diabetes in adults. It is usually given together with long-acting insulin. Insulin lispro is also used together with oral (taken by mouth) medications to treat type 2 (non insulin-dependent) diabetes in adults.
    Dosage Administration: See product insert
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin (Rapid) Regular Human
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with diabetes mellitus
    Dosage Administration: Dose depends on blood glucose, response, and many other factors. Ketoacidosis: Regular (100 units/mL) Insulin Only. IV: Adults: 0.1 unit/kg/hr as a continuous infusion. IV: Children: Loading dose: 0.1 unit/kg, then maintenance continuous infusion 0.05 –0.2 unit/kg/hr, titrate to optimal rate of decrease of serum glucose of 80 – 100mg/dL/hr. Maintenance Therapy: SC: Adults and Children: 0.5 – 1 unit/kg/day in divided doses. Adolescents during rapid growth: 0.8 – 1.2 unit/kg/day in divided doses. Treatment of Hyperkalemia: SC: IV: Adults and Children: Dextrose 0.5 – 1g/kg combined with insulin 1 unit for every 4 – 5g dextrose given.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin (Isophane) NPH
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with diabetes mellitus.
    Dosage Administration: Dose depends on blood glucose, response, and many other factors SC: Adults and Children: 0.5 – 1 unit total insulin/kg/day. Adolescents during rapid growth: 0.8 – 1.2 units total insulin/kg/day.
    View full drug info
  • Insulin and Oral Antidiabetic, Insulin (Glargine)
    Dosage form: Injection
    Strength: 100U/ml
    Indications/Special comments: Control of hyperglycaemia in patients with type 1 and type 2 diabetes mellitus.
    Dosage Administration: SC: Adults and Children =6 yr: Type 1 diabetes (insulin naïve): 1/3 of the total daily insulin dose given once daily, then adjust on the basis of patient's needs (remainder of insulin dose should be given as a short-acting insulin) (usual starting total daily insulin dose = 0.2 – 0.4 units/kg). Type 2 diabetes (insulin naïve): 0.2 units/kg or up to 10 units once daily; then adjust on the basis of patient's needs. Type 1 or 2 diabetes (and converting from Toujeo): Give 80% of Toujeo dose as Lantus once daily, then adjust on the basis of patient's needs. Type 1 or 2 diabetes (and converting from once daily NPH): Give the same dose once daily, then adjust on the basis of patient's needs. Type 1 or 2 diabetes (and converting from twice daily NPH): Give 80% of the total daily NPH dose once daily, then adjust on the basis of patient's needs.
    View full drug info
  • Immunological Preparations, Immune Globulin Intravenous (IVIG)
    Dosage form: Injection
    Strength: 3g, 5g, 6g
    Indications/Special comments: IM: Provides passive immunity to a variety of infections including: Hepatitis A, Measles (rubeola) when immune sera are unavailable or when there is insufficient time for active immunization to take place. IV: Useful in patients with immunodeficiency syndromes who are unable to produce IgG-type antibodies. Prevention of bacterial infections in patients with B-cell chronic lymphocytic leukemia (Gammagard S/D only). Prevention of bacterial infections in children infected with HIV. Treatment of idiopathic thrombocytopenic purpura (Carimune NF, Gammagard S/D, and Gamunex-C). Treatment of Kawasaki syndrome (Iveegam EN and Gammagard SD). Treatment of chronic inflammatory demyelinating polyneuropathy (Gamunex–C only). Treatment of primary immune deficiency (Gamunex-C only).SC: Treatment of primary immune deficiency
    Dosage Administration: Primary Immunodeficiency Disorder: SC: Adults and Children: Dose is administered 1 wk after IGIV dose. Dose is determined by multiplying previous IGIV dose by 1.37, then divide into weekly doses based on frequency of previous treatment. Recommended dose is 100 – 200mg/kg/wk. IV: Adults and Children: 300 – 600mg (3 – 6mL)/kg every 3 – 4 wk. Hepatitis A Prophylaxis: IM: Adults and Children: 0.02mL/kg (for pre-exposure prophylaxis, higher doses– 0.06mL/kg every 4 – 6 months are used if exposure will last >3 months). Measles Prophylaxis: IM: Adults and Children: 0.25mL/kg (0.5mL/kg if immunosuppressed; not to exceed 15mL). Immunoglobulin Deficiency: IM: Adults and Children: 1.3mL/kg initially, then 0.66mL/kg every 3 – 4 wk. Varicella: IM: Adults and Children: 0.6 – 1.2mL/kg if varicella zoster immune globulin is unavailable. Rubella: IM: Adults and Children: 0.55mL/kg. Immunodeficiency: IV: Adults and Children: 200 – 800mg (4 – 8mL)/kg monthly; if response is inadequate, may be given twice monthly. Idiopathic Thrombocytopenic Purpura: IV: Adults and Children: 0.4g/kg/day for 2 – 5 days; then 0.4g/kg single infusion as needed to maintain platelet count of 30,000 cells/mm3 or prevent bleeding; doses up to 0.8 – 1.0g/kg may be needed. IV: Adults and Children: Privigen and Gamunex–C 1g/kg daily for 2 consecutive days for a total of 2g/kg. Prevention of Bacterial Infections in HIV-Infected Patients or B cell CLL: IV: Adults and Children: 400mg/kg every 3 – 4 wk. Kawasaki Syndrome: IV: Children: 400mg/kg/day for 4 consecutive days or 1 – 2g/kg single dose given with aspirin therapy; must be started within 10 days of onset of symptoms. Chronic Inflammatory Demyelinating Polyneuropathy: IV: Adults: 2g/kg in divided doses over 2 – 4 consecutive days initially, then 1g/kg administered over one day (or 0.5g/kg administered on 2 consecutive days) every 3 wk.
    View full drug info